Unveiling the biopathway for the design of novel COMT inhibitors

Drug Discov Today. 2022 Oct;27(10):103328. doi: 10.1016/j.drudis.2022.07.013. Epub 2022 Jul 27.

Abstract

Catechol-O-methyltransferase (COMT) is an enzyme responsible for the O-methylation of biologically active catechol-based molecules. It has been associated with several neurological disorders, especially Parkinson's disease (PD), because of its involvement in catecholamine metabolism, and has been considered an important therapeutic target for central nervous system disorders. In this review, we summarize the biophysical, structural, and therapeutical relevance of COMT; the medicinal chemistry behind the development of COMT inhibitors and the application of computer-aided design to support the design of novel molecules; current methodologies for the biosynthesis, isolation, and purification of COMT; and revise existing bioanalytical approaches for the assessment of enzymatic activity in several biological matrices.

Keywords: Bioanalytical methods; COMT inhibitors; Catechol-O-methyltransferase; Computer-aided drug design; Up-/down-stream processing.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Catechol O-Methyltransferase / chemistry
  • Catechol O-Methyltransferase / metabolism
  • Catechol O-Methyltransferase Inhibitors* / chemistry
  • Catechol O-Methyltransferase Inhibitors* / pharmacology
  • Catechol O-Methyltransferase Inhibitors* / therapeutic use
  • Catecholamines
  • Catechols / chemistry
  • Central Nervous System Diseases* / drug therapy
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology
  • Humans

Substances

  • Catechol O-Methyltransferase Inhibitors
  • Catecholamines
  • Catechols
  • Enzyme Inhibitors
  • COMT protein, human
  • Catechol O-Methyltransferase